Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selective Genetics/Spinal Concepts

This article was originally published in The Gray Sheet

Executive Summary

Selective will receive up to $12 mil. from Spinal Concepts in equity purchases, license fees, R&D support or milestone payments, plus a royalty on sales, under a joint development program. The program will combine Selective's GAM gene-activated matrices with Spinal Concepts' InFix and other interbody fusion devices. Under the terms of the deal, Spinal Concepts will receive a worldwide, co-exclusive license for the use of GAM with interbody devices and will market the combined product. Selective will manufacture the GAM
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel